Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors

US9227971B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• M. Arshad Siddiqui · Newton, US
• Yang Nan · Nanjing, CN
• Mehul Patel · Blue Bell, US
• Panduranga Adulla P. Reddy · Walpole, US
• Umar Faruk Mansoor · Framingham, US
• Zhaoyang Meng · Ambler, US
• Lalanthi Dilrukshi Vitharana · Somerville, US
• Lianyun Zhao · Burlington, US
• Amit K. Mandal · Shrewsbury, US
• Duan Liu · Arlington, US
• Shuyi Tang · Shanghai, CN
• Andrew J. McRiner · Melrose, US
• David B. Belanger · Cambridge, US
• Patrick J. Curran · Saugus, US
• Chaoyang Dai · Acton, US
• Angie R. Angeles · Boston, US
• Liping Yang · Arlington, US
• Matthew H. Daniels · Somerville, US

Key dates

• Filing date: Jan 18, 2011
• Grant date: Jan 5, 2016
• Expiry date: Dec 4, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides Pyrazolopyrimidine Compounds of Formula (I):wherein L, T, Z, U, V, W, R3, R6, R7, R8, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.